Perspective Therapeutics, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q2 2011 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Perspective Therapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q2 2011 to Q3 2024.
  • Perspective Therapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending September 30, 2024 was $217K, a 87.5% decline year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $217K -$1.51M -87.5% Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $142K -$971K -87.2% Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $999K Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $1.17M -$198K -14.5% Dec 31, 2023 10-Q 2024-11-12
Q3 2023 $1.73M Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $1.11M -$495K -30.8% Jun 30, 2023 10-Q 2023-08-11
Q4 2022 $1.36M Dec 31, 2022 10-K 2024-03-28
Q2 2022 $1.61M -$405K -20.1% Jun 30, 2022 10-KT 2023-05-01
Q2 2021 $2.01M Jun 30, 2021 10-KT 2023-05-01
Q3 2015 $1.13M +$168K +17.5% Sep 30, 2015 10-Q 2015-11-09
Q2 2015 $1.05M +$136K +14.9% Jun 30, 2015 10-Q 2015-11-09
Q1 2015 $1.04M +$233K +29% Mar 31, 2015 10-Q 2015-05-15
Q4 2014 $797K -$120K -13.1% Dec 31, 2014 10-Q 2015-02-17
Q3 2014 $962K +$3.00 0% Sep 30, 2014 10-Q 2014-11-14
Q2 2014 $913K -$10.7K -1.16% Jun 30, 2014 10-K 2015-09-14
Q1 2014 $805K -$24.7K -2.98% Mar 31, 2014 10-Q 2014-05-15
Q4 2013 $917K +$261K +39.8% Dec 31, 2013 10-Q 2014-02-14
Q3 2013 $962K +$117K +13.9% Sep 30, 2013 10-Q 2013-11-14
Q2 2013 $924K +$58.7K +6.79% Jun 30, 2013 10-K 2014-09-29
Q1 2013 $830K -$23.1K -2.7% Mar 31, 2013 10-Q 2013-05-15
Q4 2012 $656K -$173K -20.8% Dec 31, 2012 10-Q 2013-02-14
Q3 2012 $845K -$127K -13.1% Sep 30, 2012 10-Q 2012-11-14
Q2 2012 $865K +$72.2K +9.11% Jun 30, 2012 10-K 2013-09-30
Q1 2012 $853K Mar 31, 2012 10-Q 2012-05-15
Q4 2011 $829K Dec 31, 2011 10-Q 2012-02-14
Q3 2011 $972K Sep 30, 2011 10-Q/A 2011-12-13
Q2 2011 $793K Jun 30, 2011 10-K/A 2012-10-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.